BY ELECTRONIC MAIL TO
|
|
- Kristin Hodge
- 6 years ago
- Views:
Transcription
1 BY ELECTRONIC MAIL TO Mr. C. Scott Tocher Interim Counsel California Institute for Regenerative Medicine 250 King Street San Francisco, CA Comments to Proposed CIRM Regulation Entitled: Intellectual Property Policy for Non Profit Organizations, [California Code of Regulations, Title 17. Public Health, Division 4 California Institute For Regenerative Medicine, Chapter 3] Dear Mr. Tocher: The California Healthcare Institute (CHI) welcomes this opportunity to comment on the California Institute for Regenerative Medicine s (CIRM) interim regulations addressing Intellectual Property Policy for Non-Profit Organizations (IPPNPO) as approved by the Independent Citizens Oversight Committee (ICOC) on February 10, CHI represents the full biomedical sector of the California economy; our members include more than 250 of California s leading life sciences companies, universities, and academic research institutions. California s highly-developed infrastructure -- including basic science, venture capital, commercial life sciences companies, along with the many support services (e.g. legal, accounting, architectural) essential to transforming scientific discoveries into products -- is the reason our state is the global leader in biotechnology. And it is the reason that public funding of embryonic stem cell research in California can exert enormous leverage. No other state in America no other nation in the world has the people and experience to capitalize on this new science as quickly as California. As the advocate for California s biomedical research and development community, CHI appreciates the ICOC s efforts to develop an intellectual property policy that conforms to the purpose and intent of Proposition 71, the California Stem Cell Research and Cures Act (Prop 71). The focus of Prop 71 is to support human embryonic stem cell research with the goal of discovering new diagnostics, treatments and therapies. We therefore support the stated objectives of the IPPNPO to promote sharing of all types of intellectual property created as a consequence of CIRM funding for use in research conducted by both academic and commercial research and development organizations and to facilitate the commercialization of CIRMfunded discoveries without impeding the progress of stem cell research. 1 1 CIRM Intellectual Property Policy for Non-Profit Organizations, approved by the ICOC on February 10, pg 4-5. H EADQUARTERS 1020 Prospect Street, Suite 310 La Jolla, California Fax S A CRAMENTO 1215 K Street, Suite 970 Sacramento, California Fax
2 Page 2 of 10 At the same time, however, CHI is concerned with the IPPNPO objective to provide a financial benefit to the State of California through revenue sharing in the event that CIRMfunded discoveries lead to valuable diagnostic and/or medical therapies and specific IPPNPO provisions addressing pricing and access requirements in technology transfer agreements. 2 Far from promoting technology transfer and commercial product development, these provisions are likely to discourage commercial interest. Because commercialization is essential for the development and production of new medicines, CHI believes that the goal of the IPPNPO should be to minimize barriers to technology transfer. Moreover, while we strongly support policies to improve access to advanced medicine, we maintain that IP policies and regulations are not the proper venue for addressing the issues of access and cost. CHI has consistently encouraged policies to regulate transaction among academic institutions and commercial companies based on the federal Bayh-Dole Act (P.L , Amendments to the Patent and Trademark Act). 3 While the IPPNPO is generally modeled on federal laws governing technology transfer 4, it includes several provisions that diverge significantly: Product pricing and access provisions that permit licensing only to organizations with plans to provide access to resultant therapies and diagnostics for uninsured California patients and only if licensees will agree to provide to patients whose therapies and diagnostics will be purchased in California by public funds the therapies and diagnostics at a cost not to exceed the federal Medicaid price ; 5 March-in rights and grounds for termination of licenses that may be exercised if the pricing and access provisions referenced above are not adhered to; 6 Recoupment and revenue-sharing provisions that, beyond a threshold amount and after payments to investors, require grantees to pay 25% of revenues received under a license agreement to the State of California for deposit into the State s General Fund; 7 and Broad, vague and ambiguous requirements that CIRM-funded inventions must be made available, by grantee organizations and licensees, for research purposes at no cost. 8 During the past thirty years, California biotechnology companies have licensed hundreds of inventions from academic institutions. The lesson from this collective experience is that stakeholders researchers and research organizations, industry and other licensees, and venture 2 Ibid 3 See Statement of David L. Gollaher, Ph.D., President and CEO, California Healthcare Institute (CHI) before the Joint Informational Hearing of the Senate Health and Human Services Committee and Assembly Health Committee, Sept. 15, Including, in addition to Bayh-Dole, P.L , the Stevenson-Wydler Technology Innovation Act (Stevenson- Wydler), as amended 5 Proposed Title 17 of California Code of Regulations, section (d) 6 Proposed Title 17 of California Code of Regulations, section (a)(2) and section (f) 7 Proposed Title 17 of California Code of Regulations, section (b) 8 Proposed Title 17 of California Code of Regulations, section and section (f)
3 Page 3 of 10 capital investors value transparency and predictability in licensing and technology transfer agreements. Biotechnology is inherently risky. Any aspect of a technology transfer contract that increases risk, particularly by adding an element of uncertainty, makes it less attractive to potential partners and investors and thus reduces the prospects for successful commercial collaboration. We address in detail our concerns regarding specific provisions below. The Life Sciences Business Model and the Impact of Bayh-Dole Intense competition for investment capital places enormous pressures on biopharmaceutical firms, whose products require years of testing to meet U.S. Food and Drug Administration (FDA) standards. On average, it takes 10 to 15 years and more than $800 million to develop a potential new medicine from a basic research discovery to a product approved by the FDA. Before FDA product approval, the value of a biomedical company depends on its patents its intellectual property. In fact, for many of the smaller firms that comprise the majority of the biomedical industry, and whose products and technologies are still in pipeline, IP is sometimes their only real asset. The biotechnology industry in California rests fundamentally on IP. Bayh-Dole, Stevenson-Wydler, and other federal policies regulating intellectual property and technology transfer have been important to the success of California s biomedical research and development enterprise. Prior to Bayh-Dole -- [T]he government [generally] retained title to inventions made with government support whether the research was performed in federal laboratories, in universities, or by individual companies. Licenses to use government patents were then negotiated with firms either on a non-exclusive basis (meaning additional companies could use the technology) or, more rarely, for the exclusive use by one manufacturer. However, it was widely argued that without title (or at least an exclusive license) to an invention and the protection it conveys, a company would not invest the additional, and substantial time and money necessary to commercialize a product or process for the marketplace. 9 Enactment of Bayh-Dole, therefore, created a single, uniform national policy designed to cut down on bureaucracy and encourage private industry to utilize government financed inventions through the commitment of the risk capital necessary to develop such inventions to the point of commercial application. 10 The licensing and technology transfer mechanisms of Bayh-Dole have had an especially significant impact on the life sciences. In California alone, since Bayh-Dole s enactment in 9 Congressional Research Service (CRS) Report RL32076, The Bayh-Dole Act: Selected Issues in Patent Policy and the Commercialization of Technology, by Wendy Schacht. Updated June 10, p House Committee on the Judiciary, Report to Accompany H.R. 6933, 96 th Congress, 2 nd Session, H.Rept , Part 1, p3. Emphasis added.
4 Page 4 of , the state s leading academic and non-profit research institutions have spun out over 600 biomedical companies through technology transfer agreements. 11 Given the federal technology transfer model s record of success in advancing biomedical research, development, and commercialization, CHI urges the ICOC to adopt an IPPNPO that is more closely in line with federal policy. Where the interim IPPNPO policy differs, we believe that the record of debate, consideration, decision-making, and experience at the federal level offers evidence of the barriers and disincentives that an overly restrictive or ambiguous policy can create. i. Proposed Title 17 of California Code of Regulations, Section (d) CHI is concerned that the ICOC may be inappropriately using the IPPNPO to address health care access and pricing issues by requiring exclusive licensing of CIRM-funded inventions only to organizations with plans to provide access to resultant therapies and diagnostics for uninsured California patients and only if licensees will agree to provide to patients whose therapies and diagnostics will be purchased in California by public funds the therapies and diagnostics at a cost not to exceed the federal Medicaid price. While improving health care access and affordability are important goals, they were not the objective of Prop 71 and should, therefore, not be the subject of policies and regulations pertaining to Prop 71. Indeed, CHI strongly believes that a stated purpose of Prop 71 to [i]mprove the California health care system and reduce the long-term health care cost burden on California through the development of therapies that treat diseases and injuries with the ultimate goal to cure them assumes that CIRM-funded research and resulting innovation will directly address these goals. 12 Requirements included in the draft IPPNPO would discourage commercial collaboration, technology transfer and licensing by (a) reducing the rate of return on CIRMrelated deals in comparison to other academic-industry transactions, and (b) increasing investors financial risk by imposing state price regulation on downstream products. Considering biotechnology s long product lead times, price regulation makes it all the more difficult to project return on investment. Experience at the federal level confirms these concerns. Technology transfer and licensing policies at the National Institutes of Health (NIH) attempted to incorporate fair pricing requirements, with poor results. According to a report by the Congressional Research Service (CRS) -- Prior to 1995, NIH had included what was known as a fair pricing clause" in its cooperative research and development agreements [CRADA] and many licensing arrangements. In 1989, the Public Health Service (PHS) instituted a policy addressing the pricing of products resulting from a government-owned patent licensed by NIH on an exclusive basis to industry or an invention jointly developed with industry under a CRADA and then licensed exclusively to the collaborator. 11 Source: PricewaterhouseCoopers/California Healthcare Institute surveys, 2002 and Text of Proposition 71, Sec. 3, Purpose and Intent
5 Page 5 of 10 The clause was removed in 1995 at the request of Dr. Harold Varmus, Director of NIH, after a review of the situation and several public hearings. He concluded that the evidence indicated "...the pricing clause has driven industry away from potentially beneficial scientific collaborations with PHS scientists without providing an offsetting benefit to the public." While sharing concerns over the "potential inaccessibility" of drugs due to costs, "NIH [agreed] with the consensus of the advisory panels that enforcement of a pricing clause would divert NIH from its primary research mission and conflict with its statutory mission to transfer promising technologies to the private sector for commercialization." A study by the Department of Health and Human Services Inspector General found that companies viewed the clause as a major problem in the NIH CRADA approach. Opponents of the clause argued that the uncertainty of the pricing clause exacerbated a process already fraught with risk. According to industry sources, not knowing what the determination of "fair" pricing would be at the end of a long and expensive research, development, and commercialization process was a strong deterrent to entering into cooperative arrangements. Many of the pharmaceutical and biotechnology companies declined to undertake CRADAs. Some firms even declined opportunities for joint clinical trials with NIH in anticipation of future price control demands. 13 (emphasis added) Based on these findings, CHI is concerned that the IPPNPO pricing and access provisions would similarly divert CIRM from its primary missions as outlined by Prop 71. Accordingly, CHI strongly urges the ICOC to remove Section (d) from the final IPPNPO. ii. Proposed Title 17 of California Code of Regulations, Section (a)(2) and Section (f) CHI is similarly concerned with the IPPNPO s grounds for termination of licenses and march-in rights, provisions and procedures, especially as they pertain to the pricing and access requirements addressed above. While based on provisions in Bayh-Dole, the IPPNPO differs notably by including among the circumstances for triggering march-in rights failure by licensees to adhere to pricing and/or access plans as described in the proposed Title 17 of California Code of Regulations, Section (d). 14 CHI maintains that these provisions present an additional disincentive to commercial collaboration. Bayh-Dole march-in provisions do not include product costs as a triggering mechanism, nonetheless several attempts have been made to persuade the federal government to exercise march-in rights based on the premise that prices of certain pharmaceutical products developed with federal funding were unreasonable. In each case, the NIH decided not to initiate march-in proceedings. 15 This history suggests that the ICOC, CIRM and licensees of CIRM-funded institutions would almost certainly face calls for the state to exercise march-in rights. The result would be to add another layer of risk and uncertainty to academic-commercial transactions. CHI therefore suggests that the ICOC remove pricing and access as grounds for both the triggering of CIRM march-in rights and the termination of licenses. 13 Congressional Research Service (CRS) Report RL32324, Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship, by Wendy Schacht. March 16, p P.L , Section See NIH March-In position paper in the case of Xalatan and NIH March-In position paper in the case of Norvir at
6 Page 6 of 10 CHI also requests, consistent with Bayh-Dole, that public use requirements addressed in Section (a)(3) be clearly specified to minimize ambiguity and uncertainty. Finally, CHI requests that the ICOC very carefully consider how to address march-in proceedings. At a minimum, the ICOC should establish detailed procedures that, in addition to the notice of determination and basis as provided in Section (b), establish the right of the patent holder, licensee, and other interested stakeholders to submit information and arguments opposing and appealing any proposed march-in prior to final action. iii. Proposed Title 17 of California Code of Regulations, Section (b) CHI acknowledges that an intent of the research funded by Prop 71 is to [provide] an opportunity for the state to benefit from royalties, patents, and licensing fees that result from the research. 16 However, we question IPPNPO provisions that would require grantees to pay, beyond a threshold amount and after payments to inventors, 25% of revenues received under a license agreement to the State of California for deposit into the State s General Fund. Beyond the request that, for the purposes of this section, the IPPNPO definition of revenues be clarified to exclude equity ownership, such as stock, stock options, etc., CHI suggests that direct revenue sharing and/or recoupment provisions may actually reduce the public benefit of Prop 71 funded research. A CRS Report for Congress succinctly summarizes the decision at the federal level not to require direct recoupment provisions Providing universities, nonprofit institutions, and small businesses with title to patents arising from federally-funded R&D offers an incentive for cooperative work and commercial application. Royalties derived from intellectual property rights provide the academic community an alternative way to support further research and the business sector a means to obtain a return on their financial contribution to the endeavor. While the idea of recoupment was considered by the Congress in hearings on [Bayh-Dole] legislation, it was rejected as an unnecessary obstacle, one which would be perceived as an additional burden to working with the government. It was thought to be particularly difficult to administer. Instead, Congress accepted as satisfactory the anticipated payback to the country through increased revenues from taxes on profits, new jobs created, improved productivity, and economic growth. For example, according to the MIT Technology Licensing Office, 15% of the sales of licensed products derived from federally funded university research is returned to the government in the form of income taxes, payroll taxes, capital gains taxes, and corporate income taxes. This is estimated to be 6 times the royalties paid by companies to the universities. The emergence of the biotechnology industry and the development of new therapeutics to improve health care are other prominent indications of such benefits. These benefits have been considered more important than the initial cost of the technology to the government or any potential unfair advantage Text of Proposition 71, Sec. 3, Purpose and Intent 17 The Bayh-Dole Act: Selected Issues in Patent Policy and the Commercialization of Technology, p. 14
7 Page 7 of 10 CHI suggests that the financial benefits to the state from CIRM-funded research and subsequent technology transfer and product commercialization will come from job creation, exports, increased income taxes, payroll taxes, capital gains taxes, corporate income taxes in short from a broad range of economic factors. We further suggest that a recoupment policy will, in fact, divert grantees financial resources from additional research activities that would otherwise be possible. We therefore request that the ICOC reconsider Section (b) of the interim IPPNPO. iv. Proposed Title 17 of California Code of Regulations, Section CHI opposes the draft IPPNPO s extremely broad and unprecedented research use exemption provision. While CHI shares the objective of ensuring that CIRM-funded inventions are made broadly available to the California research community, the provision in the IPPNPO, as written, may have several negative unintended consequences. First, it eliminates any possibility that a CIRM-funded research tool will be commercialized, because it requires that any licensee make such a research tool available to all California researchers at no cost. If all California customers must be served free, there is no commercial opportunity in embryonic stem cell related research tools. Second, it creates discriminatory treatment of the substantial research tools segment of the California life sciences industry. Prop 71 and CIRM fully recognize that commercial incentives must be preserved to get CIRM-supported therapies and diagnostics to patients in need. The premise that research and development is a two part process, with academic institutions performing basic research and commercial companies conducting applied research, development and commercialization, is fundamental to Prop 71. CHI holds that this principle should apply equally to research tools because commercialization of such inventions accelerates their broad dissemination to the research and commercial communities. Indeed, the academic and non-profit research institutes that initially develop research tools have neither the resources nor the facilities to produce and distribute them in the quantity necessary, making commercialization a fundamentally essential component to research tools dissemination. Just as therapies must reach patients to achieve health benefits, so too must new research tools for stem cell isolation, characterization, and differentiation reach investigators for stem cell research to advance at the fastest possible rate. Finally, the inclusion of such a sweeping research use provision in the IPPNPO sets a dangerous precedent at a time when research use policy is currently being debated in many forums. Given these factors, CHI urges the ICOC to use extreme caution before enacting any research use provisions. In the rationale for Sec outlined in the Statement of Reasons, reference is made to the Patent Act of 1952 and its lack of a generally applicable research exemption. 18 While exemptions from patent enforcement are rare in U.S. patent law, there are in fact two operative types of research use exemptions that will apply to CIRM grantees even in the absence of any research use provision in the IPPNPO. 18 CIRM Initial Statement of Reasons for the Proposed Adoption of Intellectual Property Regulations for Non- Profit Organizations, p 9.
8 Page 8 of 10 One exemption is the judicially created common law research-use exemption. This exemption provides that it is not an act of infringement to make and use a patented invention if the use is limited to research or experimentation and the user does not obtain any commercial advantage or benefit. There have been only a handful of cases in the 200-year history of this exemption, but in those cases the courts have interpreted this exemption narrowly. In Madey v. Duke, the Court of Appeals for the Federal Circuit held that activities that could be construed to have a business-related objective (e.g., publishable research to further a university's prestige, image, and ability to bring in grant money) are considered to be outside the scope of a research use exemption. 19 Thus, academic researchers may be outside the scope of exemption if their activities further the interests of their institutions, such as attracting researchers or securing research grants. As a practical matter however, a patent owner will generally not enforce his patent against a researcher if the research activities in question do not damage the patent owner s commercial interests. While the Madey v. Duke decision has raised many concerns in the academic community, a recent study commissioned by the National Academies indicates few instances where patents have constrained commercial or academic biomedical research, even in areas of substantial commercial interest. 20 This is true even in the post Madey v. Duke environment despite some reported activity aimed at influencing academic research or publication. A second type of research exemption is a part of the Hatch-Waxman Act of It allows making and using a patented pharmaceutical compound or device to collect data for submission to a U.S. government regulatory agency. This is a safe harbor for individuals or entities making and using patented materials for uses reasonably related to the development and submission of information to the government (e.g, the FDA). The U.S. Supreme Court recently interpreted this provision very broadly, creating a large statutory drug developmentspecific research use provision in U.S. law. 22 This statutory exemption as well as the common law research use exemption will apply to CIRM grantees absent any additional research use provision in the IPPNPO. We also point out that researchers can avoid infringement liability by obtaining authorization from patent holders for use of an invention in research. Finally, it should be noted that good non-patent related alternatives to the research use provision exist. NIH, for example, uses its Research Tool Guidelines to effectively encourage broad dissemination of NIH-funded research tools. 23 Importantly, the NIH approach focuses on the goal of broad access and preserves the flexibility to use commercial forces where they are the 19 JOHN M.J. MADEY, Plaintiff-Appellant, v. DUKE UNIVERSITY, Defendant-Appellee. UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT. 307 F.3d 1351; 2002 U.S. App. LEXIS 20823; 64 U.S.P.Q.2D (BNA) Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health, As available at U.S.C. 271(e)(1) 22 In decision on Merck KGaA v. Integra LifeSciences I, Ltd. Available at 23 See NIH Principles and Guidelines for Sharing of Biomedical Resources available at
9 Page 9 of 10 best means of achieving broad dissemination. That approach also does not risk undermining the core incentive structure that has motivated the development of so many important life science tools. Given these factors, CHI suggests that Section of the IPPNPO be removed or significantly narrowed to acknowledge existing research use exemptions along with the importance and value of commercial research tools to CIRM-funded research, commercial collaboration, and product development. Otherwise, we are concerned that this provision, as written, would eliminate any incentive for private industry to make the additional investments necessary to bring CIRM-funded research-related IP to fruition. Without private sector investment in research innovations, stem cell research and the development of resulting new treatments and therapies will be constrained. Similarly, CHI suggests that the requirement that grounds for termination of licenses include "failure to keep the licensed invention available to the public for research purposes" included in Section (f) is, as written, vague, overbroad and ambiguous for the same reasons as mentioned above with regards to Section (a)(3). Nor is that language seemingly consistent with the initial requirement of Section , which addresses California research institutions. Therefore, CHI requests that the ICOC remove or clarify this provision to better explain what purpose it is intended to serve (i.e. what other provisions of the regulations it is intended to support). Conclusion CHI appreciates this opportunity to comment on the interim CIRM Intellectual Property Policy for Non-Profit Organizations. We believe that a strong IPPNPO will advance CIRMfunded stem cell research and, ultimately, treatments for millions here in California and worldwide. This, in turn, will improve California s health care system, benefit the California economy, and further promote the state s biotechnology industry as a global leader. We hope that the ICOC will give careful consideration to our comments and incorporate them into the final IPPNPO. In summary, to promote technology transfer and commercial collaboration on CIRMfunded inventions and to limit barriers to stakeholder participation in research, licensing, and commercialization, CHI suggests that the ICOC: Remove Section (d), which permits licensing only to organizations with plans to provide access to resultant therapies and diagnostics for uninsured California patients and only if licensees will agree to provide to patients whose therapies and diagnostics will be purchased in California by public funds the therapies and diagnostics at a cost not to exceed the federal Medicaid price. Remove Section (a)(2), which sets pricing and access issues as conditions for the triggering of CIRM march-in rights.
10 Page 10 of 10 Clearly specify public use requirements addressed in Section (a)(3) in order to minimize ambiguity and uncertainty. Remove pricing and access issues as grounds for modification or termination of licenses as provided in Section (f). Remove or consider more effective and efficient alternatives to Section (b), which establishes a direct revenue-sharing policy for CIRM-funded commercialized technologies. Remove or significantly narrow Section , which broadly requires that CIRMfunded inventions must be made available for research purposes at no cost. Clarify, narrow or remove "failure to keep the licensed invention available to the public for research purposes" as grounds for termination of licenses included in Section (f). We look forward to working with the ICOC is it finalizes this policy, and we would be happy to further discuss these comments in additional detail. Thank you for your attention to this important matter. Sincerely, David L. Gollaher, Ph.D. President and CEO California Healthcare Institute cc: Mary E. Maxon, Ph.D.
BY ELECTRONIC MAIL TO
BY ELECTRONIC MAIL TO NONPROFITIPREGS@CIRM.CA.GOV Mr. C. Scott Tocher Interim Counsel California Institute for Regenerative Medicine 250 King Street San Francisco, CA 94107 Comments to Proposed Changes
More informationDe Jure and De Facto Research Use Exemptions in Patent Law
De Jure and De Facto Research Use in Patent Law Sean O Connor Associate Professor of Law Associate Director, Program in Intellectual Property Law and Center for Advanced Studies & Research on Intellectual
More informationFebruary 4, The Honorable Arlen Specter Ranking Member, Committee on the Judiciary United States Senate Washington, D.C.
UNITED STATES DEPARTMENT OF COMMERCE The Assistant Secretary for Legislative and Intergovernmental Affairs WASHINGTON, D.C. 20230 February 4, 2008 The Honorable Arlen Specter Ranking Member, Committee
More informationBiomarkers Consortium General Intellectual Property and Data Sharing Principles
Biomarkers Consortium General Intellectual Property and Data Sharing Principles I. Introduction The goals of the Biomarkers Consortium are to: 1. promote the discovery, development, qualification, and
More informationMarch-In Rights: Prospects and Alternatives
March-In Rights: Prospects and Alternatives Aaron S. Kesselheim, M.D., J.D., M.P.H. Associate Professor, Harvard Medical School Director, () February, 2017 akesselheim@partners.org What is? Core faculty
More informationFEDERAL RESEARCH. DOE Is Addressing Invention Disclosure and Other Challenges but Needs a Plan to Guide Data Management Improvements
United States Government Accountability Office Report to Congressional Requesters January 2015 FEDERAL RESEARCH DOE Is Addressing Invention Disclosure and Other Challenges but Needs a Plan to Guide Data
More informationHEARING STATEMENT. United States Senate Committee on Banking, Housing, and Urban Affairs
HEARING STATEMENT United States Senate Committee on Banking, Housing, and Urban Affairs Spurring Job Growth Through Capital Formation While Protecting Investors December 1, 2011 Executive Summary The Biotechnology
More informationApprover: Dr. Robert Steiner Executive Director, Marshfield Clinic Research Foundation
Policy # 1024.1(previous number) Policy Title: Effective Date: mm/dd/yyyy Supersedes: N/A Approver: Dr. Douglas Reding Vice President, Marshfield Clinic Date Approver: Dr. Robert Steiner Executive Director,
More informationRE: Comment on CMS-9937-P ( Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2017: Proposed Rule )
December 21, 2015 Centers for Medicare and Medicaid Services Department of Health and Human Services Hubert H. Humphrey Building, Room 445-G 200 Independence Avenue, SW Washington, D.C. 20201 RE: Comment
More informationRegulatory Priorities Governing Stem Cell Research in California: Relaxing Revenue Sharing & Safeguarding Access Plans
Berkeley Technology Law Journal Volume 23 Issue 1 Article 10 January 2008 Regulatory Priorities Governing Stem Cell Research in California: Relaxing Revenue Sharing & Safeguarding Access Plans David C.
More informationTherapeutic Goods Amendment (Pharmaceuticals Transparency) Bill Senate Finance and Public Administration Committee
Therapeutic Goods Amendment (Pharmaceuticals Transparency) Bill 2013 Senate Finance and Public Administration Committee 0 mtaa.org.au Medical technology for a healthier Australia www.mtaa.org.au Level
More informationH.R.1 `SEC HIT POLICY COMMITTEE. American Recovery and Reinvestment Act of 2009 (Engrossed as Agreed to or Passed by House)
The Library of Congress > THOMAS Home > Bills, Resolutions > Search Results THIS SEARCH THIS DOCUMENT GO TO Next Hit Forward New Bills Search Prev Hit Back HomePage Hit List Best Sections Help Contents
More informationJune 30, 2006 BY ELECTRONIC DELIVERY
June 30, 2006 BY ELECTRONIC DELIVERY Mark McClellan, M.D., Ph.D., Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building
More informationGovernment Owned, Government Operated (GOGO) Laboratories
Government Owned, Government Operated (GOGO) Laboratories Mojdeh Bahar, J.D., M.A., CLP The National Institutes of Health Nashville, Tennessee May 2, 2011 2 Mojdeh Bahar FLC Mid-Atlantic Regional Coordinator
More informationUNIVERSITY LICENSING GUIDELINES (revised October 1, 2001)
'.. UNIVERSITY LICENSING GUIDELINES revised October 1, 2001) The purpose of licensing University inventions is to provide a mechanism to encourage the practical application of the results of University
More informationTo: Vice Chancellors, Deans, Administrative Staff, Department Heads, and Students.
Chancellor s Memorandum CM-35 Conflicts of Interest in Research: Managing Potential Financial and Non-Financial Conflicts of Interest of Individuals and the Institution To: Vice Chancellors, Deans, Administrative
More informationIntellectual Property Policy
Intellectual Property Policy For Partners-Affiliated Hospitals and Institutions The Hospitals and other Institutions affiliated with Partners HealthCare System are not-for-profit corporations which share
More informationMs. Gloria Blue Office of Policy Coordination U.S. Trade Representative Submitted via December 13, Dear Ms. Blue:
Ms. Gloria Blue Office of Policy Coordination U.S. Trade Representative Submitted via e-mail December 13, 2002 Dear Ms. Blue: Please find attached the Semiconductor Industry Association's submission to
More informationSponsored Research Agreement Review Procedures Research Administration and Finance
Sponsored Research Agreement Review Procedures Research Administration and Finance I. Introduction All sponsored research agreements are negotiated by Research Administration and Finance (RAF). When negotiations
More informationS. ll IN THE SENATE OF THE UNITED STATES
OLL TH CONGRESS ST SESSION S. ll To amend the patent law to promote basic research, to stimulate publication of scientific documents, to encourage collaboration in scientific endeavors, to improve the
More informationBiotechnology Industry Organization
Written testimony of the Biotechnology Industry Organization Submitted to the United States Senate Committee on Banking, Housing, and Urban Affairs Subcommittee on Securities, Insurance, and Investment
More informationCentral Office of Research Administration
SECTION: PURPOSE STATEMENT To set forth the process for reviewing financial interests, and for identifying and addressing financial conflicts of interest ( FCOI ) in Research (as defined later in this
More informationRe: Medicare Prescription Drug Benefit Manual Draft Chapter 6
September 26, 2006 BY ELECTRONIC DELIVERY Cynthia Tudor, Ph.D. Director, Medicare Drug Benefit Group Centers for Medicare & Medicaid Services Mail Stop C4-13-01 7500 Security Boulevard Baltimore, MD 21244
More informationMay 7, Notice of Proposed Rulemaking and Notice of Public Hearing on Taxable Medical Devices (77 Fed. Reg. 6,028 [Feb. 7, 2012].
May 7, 2012 VIA COURIER AND ELECTRONIC MAIL Courier s Desk Attn: CC:PA:LPD:PR (REG-113770-10) Internal Revenue Service 1111 Constitution Ave, N.W. Washington, DC 20224 RE: Notice of Proposed Rulemaking
More informationDrug Royalty II $701,420,000. Presentation to: San Diego County Employees Retirement Association
Drug Royalty II $701,420,000 Presentation to: San Diego County Employees Retirement Association November 2010 Profile Business Model Team Investment Criteria To acquire Royalty Streams on established commercialized
More informationStatement Of the U.S. Chamber Of Commerce
Statement Of the U.S. Chamber Of Commerce ON: TO: Hearing on Extension of Certain Expired and Expiring Tax Provisions Senate Finance Committee DATE: January 31, 2012 The Chamber s mission is to advance
More informationRE: Additional Input regarding Accountable Care Organizations (ACOs) and the Medicare Shared Saving Program
221 MAIN STREET, SUITE 1500 SAN FRANCISCO, CA 94105 PBGH.ORG OFFICE 415.281.8660 FACSIMILE 415.520.0927 February 14, 2011 Donald M. Berwick, M.D. Administrator Centers for Medicare and Medicaid Services
More informationTechnology Transfer Office as a Business Unit
Page 1 Currently,, is vice president, technology transfer, at the M. D. Anderson Cancer Center in Houston, Texas. However, he wrote this chapter while he was director of technology management at the University
More informationOIG 127 N: Solicitation of New Safe Harbors and Special Fraud Alerts
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org By Electronic Submission via www.regulations.gov Ms. Patrice Drew Office of Inspector
More informationIncentives for Nondiscriminatory Wellness Programs in Group Health Plans
Office of Health Plan Standards and Compliance Assistance Employee Benefits Security Administration Room N-5653 U.S. Department of Labor 200 Constitution Avenue NW Washington, DC 20210 Re: Dear Sir or
More informationMarch 29, kpmg.com
U.S. tax reform Planning in uncertain times Forward-thinking life sciences companies may want to consider the impact of potential tax reform on their supply chain, R&D, and more March 29, 2017 In light
More informationTestimony of David B. Kelley, Intellectual Property Counsel Ford Global Technologies, LLC
Testimony of David B. Kelley, Intellectual Property Counsel Ford Global Technologies, LLC Before the House Judiciary Subcommittee on Intellectual Property, Competition and the Internet Regarding Certain
More informationJune Dear Fellow Takeda Shareholder,
June 2018 Dear Fellow Takeda Shareholder, Since joining Takeda in April 2014, my mission has been to continue the transformation of Takeda in order to ensure that Takeda will be a successful company in
More informationGEORGETOWN LAW. Georgetown University Law Center. CIS-No.: 2006-H
Georgetown University Law Center Scholarship @ GEORGETOWN LAW 2006 Bill To Amend Title 35, U.S. Code, To Conform Certain Filing Provisions Within the Patent and Trademark Office, 109th Cong., Sept. 14,
More informationComments on Certain Preventive Services Under the Affordable Care Act, CMS-9968-ANPRM
June 18, 2012 Secretary Kathleen Sebelius US Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Re: Comments on Certain Preventive Services Under the Affordable Care
More informationComments to the Patent Public Advisory Committee Public Hearing on the Proposed Patent Fee Schedule [Docket No. PTO-P ]
Brendan Hourigan Director, Office of Planning and Budget Office of the Chief Financial Officer United States Patent and Trademark Office 600 Dulany Street Alexandria, VA 22314 Via email: fee.setting@uspto.gov
More informationFINANCIAL CONFLICT OF INTEREST POLICY
FINANCIAL CONFLICT OF INTEREST POLICY Individuals who are appointed to serve on ABIM boards or committees are expected to have the American Board of Internal Medicine s (ABIM) mission as their primary
More informationRe: Medicare Program; Request for Information Regarding the Physician Self-Referral Law [CMS NC]
August 24, 2018 The Honorable Seema Verma Administrator Centers for Medicare & Medicaid Services Department of Health & Human Services Attention: CMS-1693-P P.O. Box 8016 Baltimore, MD 21244-8016 Submitted
More informationEnsure Network Adequacy. May 23, 2017
May 23, 2017 The Honorable Orrin Hatch Chairman, Senate Finance Committee 219 Dirksen Senate Office Building Washington, DC 20510 Sent electronically to HealthReform@finance.senate.gov Dear Mr. Chairman,
More informationCannabics Pharmaceuticals, Inc. Breakthrough Cannabis Medications - Review and Outlook.
Cannabics Pharmaceuticals, Inc. Breakthrough Cannabis Medications - Review and Outlook. Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), is engaged in the development of Personalized Anti- Cancer treatments.
More informationReporting of In-direct Transfers of Value
February 17, 2012 Marilyn B. Tavenner Acting Administrator Chief Operating Officer Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G, Hubert H. Humphrey Building
More informationUnited States Senate Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights
Testimony United States Senate Committee on the Judiciary Hospital Group Purchasing: How to Maintain Innovation and Cost Savings September 14, 2004 Dr. Robert Betz President and CEO, Health Industry Group
More informationINSTITUTE OF MEDICINE COMMITTEE ON THE DETERMINATION OF ESSENTIAL HEALTH BENEFITS
COMMENTS 1310 G Street, N.W. Washington, D.C. 20005 202.626.4780 Fax 202.626.4833 Before the INSTITUTE OF MEDICINE COMMITTEE ON THE DETERMINATION OF ESSENTIAL HEALTH BENEFITS On How Insurers Make Determinations
More informationFinancial Conflict of Interest. V001 November 14, 2014
Financial Conflict of Interest November 14, 2014 Table of Contents 1 Policy Description... 3 2 Introduction and Scope... 3 3 Definitions... 3 3.1 Terms... 3 3.2 Acronyms... 4 4 Procedure... 5 4.1 Part
More informationTX Health and Human Services Commission Proposed Rule: 340B Program Reimbursement
January 31, 2014 VIA ELECTRONIC SUBMISSION Vendor Drug Program Medicaid/CHIP Division 4900 N. Lamar Austin, Texas 78751 RE: TX Health and Human Services Commission Proposed Rule: 340B Program Reimbursement
More informationAlternative Investment Management Association
By email only to: rule-comments@sec.gov Dear Sirs 19 June 2009 AIMA s comments on the new short sale rules proposed by the Securities and Exchange Commission AIMA 1 is pleased to have the opportunity to
More informationA. As Currently Implemented, the Recovery Purchasing Program Is Not Truly Voluntary for FSS Contractors Under Schedule 65, Part I, Section B.
April 2, 2007 Ms. Laurieann Duarte General Services Administration Regulatory Secretariat (VIR) 1800 F Street, NW Room 4035 Washington, D.C. 20405 Dear Ms. Duarte: Re: Amendment 2007-01, GSAR Case 2006-G522;
More informationRE: Medicare Coverage Gap Discount Program Appeals Guidance
Cynthia G. Tudor, Ph.D., Director, Medicare Drug Benefit and C & D Data Group Centers for Medicare and Medicaid Services Department of Health and Human Services 7500 Security Boulevard Baltimore, Maryland
More informationcc: Thomas West, Tax Legislative Counsel, Department of the Treasury
Matt Haller (202) 662-0770 Senior Vice President of Government Relations & Public Affairs International Franchise Association June 9, 2018 The Honorable David J. Kautter Assistant Secretary for Tax Policy
More informationRUTGERS POLICY PATENT POLICY OF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
RUTGERS POLICY Section: 50.3.1 Section Title: Legal Matters Policy Name: Patent Policy Formerly Book: 6.4.1 Approval Authority: Board of Governors Responsible Executive: Executive Vice President for Academic
More informationRe: Department of Health and Human Services: Promoting Healthcare Choice and Competition Across the United States
Assistant Secretary for Planning and Evaluation Room 415F U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, D.C. 20201 Submitted via email CompetitionRFI@hhs.gov Re:
More informationSummary of ICI and IDC Comments on the SEC s Liquidity Risk Management Proposal
The Honorable Mary Jo White Chair Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Summary of ICI and IDC Comments on the SEC s Liquidity Risk Management Proposal Dear Chair
More informationMr. Alp Eroglu International Organization of Securities Commissions (IOSCO) Calle Oquendo Madrid Spain
Mr. Alp Eroglu International Organization of Securities Commissions (IOSCO) Calle Oquendo 12 28006 Madrid Spain Dear Mr. Eroglu: Re: Consultation Report CR01/03 on Financial Benchmarks The Investment Company
More informationJanuary 21, 2008 Decision: PMPRB-07-D1-THALOMID Motion Application for Board Order (Statutory Filings)
January 21, 2008 Decision: PMPRB-07-D1-THALOMID Motion Application for Board Order (Statutory Filings) IN THE MATTER OF the Patent Act R.S.C. 1985, c. P-4, as amended AND IN THE MATTER OF Celgene Corporation
More informationGolden Gate Restaurant Association. Vs. City & County of San Francisco
A Special Report Prepared By: The Self-Insurance Institute of America, Inc. Golden Gate Restaurant Association Vs. City & County of San Francisco July 1, 2008 www.siia.org SIIA Special Report: Employer
More informationCONFLICTS OF INTEREST IN RESEARCH
IM&COI POLICY III CONFLICTS OF INTEREST IN RESEARCH (Capitalized terms are defined in the Glossary.) Presumption Against Participating in Research When Personal Financial Interests Exist If an Investigator
More informationJohns Hopkins University. Policy on Individual Financial Interests and Financial Conflict of Interests 1, 2 in Research
Johns Hopkins University Policy on Individual Financial Interests and Financial Conflict of Interests 1, 2 in Research This policy applies to the Bloomberg School of Public Health, Krieger School of Arts
More informationTHE SCHWAB BUILDING 101 MONTGOMERY STREET SAN FRANCISCO, CA (415)
charles SCHWAB THE SCHWAB BUILDING 101 MONTGOMERY STREET SAN FRANCISCO, CA 94104 (415) 636-7000 April 19, 2005 Barbara Z. Sweeney Office of the Corporate Secretary NASD 1735 K Street, NW Washington, DC
More informationNERF License Rights: Factors to Consider When Exercising NERF Pilot Program Authority
NERF License Rights: Factors to Consider When Exercising NERF Pilot Program Authority INTRODUCTION This guidance document provides a discussion of factors for consideration when contemplating the commitment
More informationCONFLICT OF INTEREST: ACCP PUBLICATIONS POLICY AND PROCEDURE
CONFLICT OF INTEREST: ACCP PUBLICATIONS POLICY AND PROCEDURE Background In August 1999, the ACCP Board of Regents approved the policy, Conflict of Interest: ACCP Publications Policy and Procedure. At its
More informationThe Harm Trigger. Section 2 (Purpose and Intent) and the Risks to Uniformity
Thanks Jennifer. I talked to my folks and the general thought is that they are supportive of version of 2A that you presented on the call last week. In terms of some potential enhancements here is our
More informationRe: Medicare Prescription Drug Benefit Manual Draft Chapter 5
September 18, 2006 BY ELECTRONIC DELIVERY Cynthia Tudor, Ph.D. Director, Medicare Drug Benefit Group Centers for Medicare and Medicaid Services Department of Health and Human Services Mail Stop C4-13-01
More informationBy 13 September Dear Mr. Andrus,
Transfer Pricing Associates B.V. H.J.E. Wenckebachweg 210 1096AS Amsterdam The Netherlands T +31 (0)20 462 3530 F +31 (0)20 462 3535 www.tpa-global.com Attn. Mr. Joseph Andrus Organisation for Economic
More informationSecond and Fifth Circuits Split on Who is Entitled to Whistleblower Protection Under Dodd-Frank
H Reprinted with permission from the Employee Relations LAW JOURNAL Vol. 41, No. 4 Spring 2016 SPLIT CIRCUITS Second and Fifth Circuits Split on Who is Entitled to Whistleblower Protection Under Dodd-Frank
More informationStatement of the U.S. Chamber Of Commerce
Statement of the U.S. Chamber Of Commerce ON: TO: Hearing on Extension of Certain Expired and Expiring Tax Provisions Subcommittee on Select Revenue Measures of the Ways & Means Committee DATE: April 26,
More informationIndustry Insight Accounting Update for the Life Sciences Industry
Industry Insight Accounting Update for the Life Sciences Industry This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial,
More informationAMCP Foundation Symposium Specialty Pharmacy and Patient Care: Are We at a Tipping Point? Disclaimer
AMCP Foundation Symposium Specialty Pharmacy and Patient Care: Are We at a Tipping Point? October 7, 2014 Boston, MA Disclaimer Organizations may not re use material presented at this AMCP session for
More informationApril 10, Major General Elder Granger Deputy Director, TMA Skyline Five, Suite Leesburg Pike Falls Church, VA
Major General Elder Granger Deputy Director, TMA Skyline Five, Suite 810 5111 Leesburg Pike Falls Church, VA 22041-3206 Re: Dear Manufacturer Letter Dated February 1, 2008 Dear : The Biotechnology Industry
More informationSolicitation of Public Comments on the Protecting Access to Medicare Act (PAMA)
ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. Advocacy. 9650 Rockville Pike, Suite 205, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7995 amp@amp.org www.amp.org
More informationTHE FUTURE OF ROCKEFELLER INSIGHTS. David K. Song, M.D., Ph.D., CFA Senior Portfolio Manager and Managing Director
ROCKEFELLER INSIGHTS THE FUTURE OF H E A LT H C A R E David K. Song, M.D., Ph.D., CFA Senior Portfolio Manager and Managing Director Rolando Morillo Equity Analyst and Vice President R O C K C O.C O M
More informationConflict of Interest Policy. Approved May 2016 Mayo Clinic Board of Governors
Conflict of Interest Policy Approved May 2016 Mayo Clinic Board of Governors Table of Contents I. Overview... 4 A. Guiding Principles... 4 B. What is a Conflict of Interest?... 4 C. What Can Cause a Financial
More informationMarch 1, Dear Mr. Kouzoukas:
March 1, 2019 Mr. Demetrios L. Kouzoukas Principal Deputy Administrator and Director Center for Medicare Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Advance
More informationThe SEC s Proposed Regulation Best Interest, Form CRS Relationship Summary, and Interpretation Regarding Standards of Conduct for Investment Advisers
Brent J. Fields Secretary Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Re: The SEC s Proposed Regulation Best Interest, Form CRS Relationship Summary, and Interpretation Regarding
More informationCOMMITTEE ON EMPLOYEE BENEFITS & EXECUTIVE COMPENSATION. August 13, By first-class mail and [http://www.regulations.
COMMITTEE ON EMPLOYEE BENEFITS & EXECUTIVE COMPENSATION MATTHEW L. EILENBERG CHAIR 875 THIRD AVENUE 17 TH FLOOR NEW YORK, NY 10022-6225 Phone: (212) 251-5718 Fax: (212) 644-7432 matthew.eilenberg@towerswatson.com
More informationLicensing Issues in the Life Sciences Industry: Negotiating University License Agreements
Licensing Issues in the Life Sciences Industry: Negotiating University License Agreements Monday, March 5, 2018 Scott J. Catlin, Associate Vice President for Technology Ventures at UR Ventures - University
More informationOIG 125 N: Solicitation of New Safe Harbors and Special Fraud Alerts
701 Pennsylvania Avenue, NW, Suite 800 Washington, DC 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org By Electronic Submission via www.regulations.gov Ms. Patrice Drew Office of Inspector
More informationTechnical Line FASB final guidance
No. 2017-22 Updated 4 December 2017 Technical Line FASB final guidance How the new revenue standard affects life sciences entities In this issue: Overview... 1 Collaborative arrangements... 2 Effect of
More informationCLARION UNIVERSITY OF PENNSYLVANIA Clarion, Pennsylvania Conflict of Interest Policy Research and Sponsored Projects
CLARION UNIVERSITY OF PENNSYLVANIA Clarion, Pennsylvania 16214 Conflict of Interest Policy Research and Sponsored Projects Objective/Purpose This Conflict of Interest Policy for Research and Sponsored
More informationREPORT OF THE COUNCIL ON MEDICAL SERVICE. (J. Leonard Lichtenfeld, MD, Chair)
REPORT OF THE COUNCIL ON MEDICAL SERVICE CMS Report -A-0 Subject: Presented by: Referred to: Appropriate Hospital Charges David O. Barbe, MD, Chair Reference Committee G (J. Leonard Lichtenfeld, MD, Chair)
More informationSubject: ICC s perspectives on the taxation of technical services
Mr Michael Lennard Chief, International Tax Cooperation Section Financing for Development Office U.N. Dept. of Economic and Social Affairs 2 U.N. Plaza (1st Avenue and 44th St) Room DC2-2148 United Nations,
More informationCPR Comment Letter on Short-Term, Limited-Duration Insurance (RIN 0938-AT48) Dear Secretary Azar, Secretary Mnuchin, and Secretary Acosta:
April 23, 2018 VIA ELECTRONIC SUBMISSION The Honorable Alex Azar Secretary, U.S. Department of Health and Human Services 200 Independence Ave SW Washington, DC 20201 The Honorable Steven Mnuchin Secretary,
More informationSubmitted electronically via March 5, 2018
Submitted electronically via www.regulations.gov. Ms. Jeanne Klinefelter Wilson Deputy Assistant Secretary Office of Regulations and Interpretations Employee Benefits Security Administration Room N-5655
More informationPolicy on Conflicts of Interest in Clinical Care
Policy on Conflicts of Interest in Clinical Care Approved by FPP Board of Directors: March 16, 2006 Revised and Approved: December 15, 2009, January 18, 2011, January 22, 2013, January 21, 2014, April
More informationRe: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of- Pocket Expenses [CMS-4180-P]
January 25, 2019 Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-4180-P P.O. Box 8013 Baltimore, MD 21244-8013 Re: Modernizing
More informationMAIMONIDES MEDICAL CENTER SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH
MAIMONIDES MEDICAL CENTER CODE: RES-021 (Reissued) ORIGINALLY ISSUED: October 22, 2009 SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH I. POLICY Consistent with current law and to
More informationWomen and Employer Mandates
Some health care reform proposals include an employer mandate, which typically requires an employer of a certain size and/or with certain annual business revenue to contribute towards the health care of
More informationPolicy Proposals for Reducing Health Care Costs. Marc Boutin, JD Chief Executive Officer
Policy Proposals for Reducing Health Care Costs Marc Boutin, JD Chief Executive Officer April 25, 2017 Project Goal and Approach Develop policy recommendations from the patient perspective about health
More informationOur commentary focuses on five main issues. Supplementary comments relating to specific paragraphs or issues are provided in the appendix.
Comments on the Revised Discussion Draft on Transfer Pricing Aspects of Intangibles by the Confederation of Netherlands Industry and Employers (VNO-NCW) We are pleased to see the significant progress which
More informationThe Translational Genomics Research Institute and Affiliates For the Period January 1 through November 16, 2016 With Report of Independent Auditors
C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S, R E P O R T S, S U P P L E M E N T A R Y I N F O R M A T I O N AND S C H E D U L E R E Q U I R E D B Y T H E U N I F O R M G U I D A N C E
More informationRe: CY 2018 CLFS - Preliminary Payment Rates and Crosswalking/Gapfilling Determinations; Comments submitted to
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Re: CY 2018 CLFS - Preliminary Payment Rates and Crosswalking/Gapfilling Determinations;
More informationCAROLINA EXPRESS USER GUIDE
CAROLINA EXPRESS USER GUIDE Introduction 2 Carolina Express Approval Business Plan Review Procedures 3 Carolina Express Operations Management and Communications 5 Patent Prosecution Procedures 6 References
More informationPriority Rights and AIA Drafting Error; Universities at Risk
Priority Rights and AIA Drafting Error; Universities at Risk Noted patent law expert Andrew S. Baluch has uncovered a drafting flaw in the Leahy Smith America Invents Act of 2011 that jeopardizes priority
More informationWaters Corporation Management Presentation
Waters Corporation Management Presentation Chris O Connell Chairman & Chief Executive Officer January 2019 Cautionary Statements This presentation may contain forward-looking statements regarding future
More informationSALK INSTITUTE FOR BIOLOGICAL STUDIES PATENT AND INVENTION POLICY
SALK INSTITUTE FOR BIOLOGICAL STUDIES PATENT AND INVENTION POLICY Effective July 1, 2010 (11.03.15) 1. GENERAL POLICY AND OBJECTIVES One of the primary objectives of the Salk Institute for Biological Studies
More informationFederal Financial Analytics, Inc.
Federal Financial Analytics, Inc. Managing Partner August 21, 2018 Secretariat to the Financial Stability Board Centralbahnplatz 2 CH-4002 Basel, Switzerland RE: Evaluation of the effects of financial
More informationAugust 30, Via to
Via email to rule-comments@sec.gov Elizabeth M. Murphy Secretary Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-1090 Re: Study Regarding Obligations of Brokers, Dealers, and
More informationSTATEMENT FOR THE RECORD GEORGE P. SLOVER CONSUMERS UNION BEFORE THE
STATEMENT FOR THE RECORD GEORGE P. SLOVER CONSUMERS UNION BEFORE THE SUBCOMMITTEE ON ANTITRUST, COMPETITION POLICY, AND CONSUMER RIGHTS COMMITTEE ON THE JUDICIARY UNITED STATES SENATE ON PAY-FOR-DELAY
More informationIntellectual Property Policy EFFECTIVE AS OF OCTOBER 1, 2018
Intellectual Property Policy EFFECTIVE AS OF OCTOBER 1, 2018 For Partners-Ailiated Hospitals and Institutions The hospitals and other institutions ailiated with Partners HealthCare System are not-for-proit
More informationJim Nussle President & CEO. Phone:
Jim Nussle President & CEO 99 M Street SE Suite 300 Washington, DC 20003-3799 Phone: 202-508-6745 jnussle@cuna.coop March 11, 2019 The Honorable Mike Crapo Chairman Committee on Banking, Housing and Urban
More informationPriority Employer Issues for Senate Consideration of the Patient Protection and Affordable Care Act
November 30, 2009 Priority Employer Issues for Senate Consideration of the Patient Protection and Affordable Care Act PRIORITY HEALTH REFORM PROVISIONS I. ERISA (Retain exclusive federal regulation of
More information